<DOC>
	<DOCNO>NCT01373515</DOCNO>
	<brief_summary>This open label phase 1 feasibility safety dose escalation study . The main objective evaluate safety DCP-001 intradermal vaccination patient AML .</brief_summary>
	<brief_title>Leukemic Dendritic Cell Vaccination Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>DCPrime test allogeneic ( non-self cell , standardise product ) DC-based immunotherapy cancer patient . The technology consist sustainable dendritic progenitor cell ( name `` DCOne™ '' ) proprietary method expand create functional mature dendritic cell ( DCP-001 ) . AML fast grow form leukemia particularly elderly ( &gt; 60 ) life threaten . As age important factor determine success AML treatment , overall , AML bad prognosis 24 % patient alive 5 year diagnosis . Without treatment AML fatal , usually within month . Chemotherapy cure patient prolong survival responder ; however , chemotherapy also quite toxic cause substantial morbidity mortality . The commonly prescribe first line therapy patient AML combination anthracycline cytarabine ; Western world anthracycline either daunorubicin idarubicin . Post remission therapy ( consolidation therapy ) usually give . There therefore substantial medical need new treatment modality . One major difficulty regard development new agent relatively low response rate toxicity issue way approval new agent . Immunotherapy , particular therapeutic vaccine , expect potential prevention recurrence disease cytoreductive therapy . Any drug could prevent reduce minimal residual disease population likely meet strong medical need population high risk patient . In phase 1 trial consecutive eligible patient treat 12 patient complete study . Patients start vaccination program within 2 month achieve complete remission patient stable disease least 2 month period . The first cohort ( n=3 ) receive 4 bi-weekly vaccination 1x10E7 DCP-001 , second cohort ( n=3 ) receive 4 bi-weekly vaccination 2.5x10E7 DCP-001 , last cohort ( n=3 ) receive 4 bi-weekly vaccination 5x10E7 DCP-001 . The Dose Limiting Toxicity ( DTL ) define non-hematological toxicity ≥ 3 accord common toxicity criterion v3.0 . The 4th cohort ( match HLA-A2 ) receive 4 vaccination high dose ( 5x10E7 DCP-001 ) , case turn toxic ( determined vaccination profile cohort 1 , 2 3 ) , group receive Maximum Tolerated Dose ( MTD ) . DCP-001 vaccine present direct injectable sterile cell suspension consist irradiated mature dendritic cell cryopreservation solution pack vial . The vaccine administer intradermally .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients AML , second complete remission AML ( FABsubclasses ) , eligible additional intensification therapy e.g . allogeneic ( allo ) PSCT [ independent age ] ; OR Patients relapse ( smoulder ) AML eligible additional intensification therapy e.g . alloPSCT ; OR Patients de novo ( smoulder ) AML eligible intensive treatment accord current HOVON trial . Patients &gt; 65 year age de novo AML first CR protocol current HOVON trial . WHO performance 0 , 1 , 2 . Male female patient least 18 year age &lt; 80 year date enrolment . Patients treat within current HOVON AML trial . Ability willingness give inform consent . HLAA2.1 positive patient ( cohort 4 ) . Uncontrolled active infection . Previous immunotherapy last 3 month ( except antiCD33 target therapy ) . Previous allogeneic PSCT . Inadequate bone marrow function : absolute neutrophile count ( ANC ) &lt; 0.5x10E9/L , platelet count &lt; 20x10E9/L active bleed platelet count &gt; 20x10E9/L . Inadequate liver function , define : Serum ( total ) bilirubin &gt; 1.5 x upper limit normal ( ULN ) AST/SGOT ALT/SGPT &gt; 2.5 x ULN Alkaline phosphatase level &gt; 2.5 time ULN baseline . Inadequate renal function , define : Serum creatinine &gt; 1.5 x ULN Other malignancy within last 5 year , except adequately treat carcinoma situ cervix squamous carcinoma skin , adequately control limited basal cell skin cancer . Pregnant lactating female . Serum pregnancy test assess within 7 day prior study treatment start , within 14 day confirmatory urine pregnancy test within 7 day prior study treatment start . Women childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) use effective , nonhormonal mean contraception ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly ) . Major surgical procedure ( include open biopsy ) within 28 day prior first study treatment , anticipation need major surgery course study treatment . Minor surgical procedure , within 24 hour prior first study treatment . Uncontrolled hypertension ( systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg ) clinically significant ( i.e . active ) cardiovascular disease : cerebrovascular accident ( CVA ) / stroke within ≤ 6 month prior first study treatment , unstable angina , New York Heart Association ( NYHA ) Grade II great congestive heart failure ( CHF ) , serious cardiac arrhythmia require medication . Known hypersensitivity study drug excipients . Evidence medical condition ( psychiatric illness , physical examination laboratory finding may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication . Eligibility HOVON93 study ( intensification program ± allogeneic stem cell transplant ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>DCOne</keyword>
	<keyword>DCP-001</keyword>
	<keyword>Second complete remission AML</keyword>
	<keyword>Relapse AML</keyword>
</DOC>